Oncotarget

Research Papers:

A small molecule regulator of tissue transglutaminase conformation inhibits the malignant phenotype of cancer cells

William P. Katt, Nicolas J. Blobel, Svetlana Komarova, Marc A. Antonyak, Ichiro Nakano and Richard A. Cerione _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Press Release  |  Order a Reprint

Oncotarget. 2018; 9:34379-34397. https://doi.org/10.18632/oncotarget.26193

Metrics: PDF 529 views  |   HTML 1192 views  |   ?  


Abstract

William P. Katt1, Nicolas J. Blobel1, Svetlana Komarova2, Marc A. Antonyak1, Ichiro Nakano2 and Richard A. Cerione1,3

1Department of Molecular Medicine, Cornell University, Ithaca, NY, USA

2Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA

3Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY, USA

Correspondence to:

Richard A. Cerione, email: rac1@cornell.edu

Keywords: transglutaminase; glioblastoma; signaling; glioma stem cells; cancer

Received: July 25, 2018     Accepted: September 15, 2018     Published: September 28, 2018

ABSTRACT

The protein crosslinking enzyme tissue transglutaminase (tTG) is an acyltransferase which catalyzes transamidation reactions between two proteins, or between a protein and a polyamine. It is frequently overexpressed in several different types of human cancer cells, where it has been shown to contribute to their growth, survival, and invasiveness. tTG is capable of adopting two distinct conformational states: a protein crosslinking active (“open”) state, and a GTP-bound, crosslinking inactive (“closed”) state. We have previously shown that the ectopic expression of mutant forms of tTG, which constitutively adopt the open conformation, are toxic to cells. This raises the possibility that strategies directed toward causing tTG to maintain an open state could potentially provide a therapeutic benefit for cancers in which tTG is highly expressed. Here, we report the identification of a small molecule, TTGM 5826, which stabilizes the open conformation of tTG. Treatment of breast and brain cancer cell lines, as well as glioma stem cells, with this molecule broadly inhibits their transformed phenotypes. Thus, TTGM 5826 represents the lead compound for a new class of small molecules that promote the toxicity of cancer cells by stabilizing the open state of tTG.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26193